How Natco defied the odds to rise up India#39;s pharma ladder

How Natco defied the odds to rise up India#39;s pharma ladder Copaxone is expected to deliver another windfall in FY19 for Natco, before tapering-off slowly in FY20 with the launches from other generic rivals.

No comments:

Post a Comment